Palvella Therapeutics, Inc. (FRA:PI6)

Germany flag Germany · Delayed Price · Currency is EUR
69.50
+2.50 (3.73%)
At close: Feb 20, 2026
Market Cap860.61M +441.3%
Revenue (ttm)n/a
Net Income-27.59M
EPS-3.00
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume12
Open69.50
Previous Close67.00
Day's Range69.50 - 69.50
52-Week Range17.10 - 94.00
Betan/a
RSI47.63
Earnings DateMar 31, 2026

About Palvella Therapeutics

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Way... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Wesley Kaupinen
Employees 14
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PI6
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements